Aru Pharma

Aru Biopharma is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for the treatment of autoimmune and inflammatory diseases. The company's primary focus is on targeting Toll-like receptors (TLRs), specifically TLR7, TLR8, and TLR9, which play a critical role in the innate immune response and the pathogenesis of various autoimmune conditions. Their lead programs aim to provide potent and selective inhibition to address unmet needs in diseases such as systemic lupus erythematosus (SLE) and cutaneous lupus. Aru Biopharma is headquartered in Bedminster, New Jersey, and is led by a team with extensive experience in drug discovery and immunology.